All News

We want to hear from you!

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how specialty pharmacists can show their value during the NASP Annual Meeting in Washington, DC.

With expanding pharmacy practice, it is time to explore conflict management, and its necessity in this current climate.

One health care organization has taken their flu vaccination efforts to the next level, by vaccinating the majority of its 12,000 employees, during a 1-day event called #HitMeWithYourFluShot.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

Although vitamin E acetate was identified in all bronchoalveolar fluid samples from patients who suffered lung injuries associated with vaping, THC was identified in 82% of the samples and nicotine was identified in 62%.

A supplemental New Drug Application (sNDA) was submitted to the FDA for ibrutinib (Imbruvica, AbbVie) in combination with rituximab for the first-line treatment of younger patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

With this approval, luspatercept-aamt (Reblozyl, Celgene) is the first FDA-approved erythroid maturation agent for anemia in beta thalassemia

Louisiana and Nevada show the highest flu activity in the first monthly report from the Walgreens Flu Index for October, which shows increased incidence of the flu compared with last year.

Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.

A phase 3 study evaluated ixazomib (Ninlaro, Takeda) in the first-line maintenance therapy setting for patients with multiple myeloma who have not undergone autologous stem cell transplant.

The discovery is the first time a new subtype of HIV-1 has been identified since 2000.

Top news of the day from across the health care landscape.

Because cystic fibrosis transmembrane conductance regulator modulator therapies are new, researchers sought to understand patient adherence as well as potential challenges.

Top news of the week from Specialty Pharmacy Times.

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

According to a study by PMR, the global flu vaccine market is projected to account for a market value of approximately $8 billion by the end of 2029. Increasing vaccination rates and a focus on preventive rather than reactive methods are expected to drive the growth of the market.

Top news of the day from across the health care landscape.

In an interview with Pharmacy Times®, Claire Morton Reynolds, MBA, senior industry analyst of Nutrition Business Journal (NBJ), said that homeopathic medicine may be the industry to watch on pharmacy shelves.

The US Food and Drug Administration (FDA) has authorized marketing of the Sentosa SQ HIV Genotyping Assay, a test that detects HIV-1 drug resistance mutations using next-generation sequencing technology.

The ADMIRAL trial found that gilteritinib is a significant addition to the treatments available for patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss why data standardization is important in specialty pharmacy and how technology plays into it during the NASP Annual Meeting in Washington, DC.

According to a new study by researchers at The Lundquist Institute and the University of Rochester, e-cigarette or vaping use can damage the lungs after as little as 3 days of use.

In the studies of Biktarvy from Gilead Sciences, the treatment demonstrated high rates of virologic suppression through week 144 and was found to be well-tolerated.

Medication errors associated with OTC cough and cold products highlight an important counseling opportunity for community pharmacists that is particularly relevant as winter approaches.

Informed by the newly released NCPA 2019 Digest, members of community pharmacy organizations elaborate on the ongoing discussion of value-based care and reimbursement for community pharmacists.

For otherwise healthy patients, natural products can help alleviate flu symptoms when antivirals are not indicated.